Medical Marijuana Inc (OTCMKTS:MJNA) Continues Its International Expansion

On June 19, 2017, Mexican President Enrique Peña Nieto officially published a bill making medical cannabis legal and available in Mexico. The Marijuana legalization trend now encompasses all of North America. Cannabis companies are now scrambling to establish a presence in Mexico. Medical Marijuana Inc (OTCMKTS:MJNA) is one such company that is taking steps to expand into Mexico.We’ll first give you some background on the Company. Medical Marijuana Inc is the first publicly held company vested in the cannabis and industrial hemp space in America. Through its subsidiaries and investment holdings, the Company focuses on the development, sale and distribution of hemp oil that contains naturally occurring cannabinoids, including cannabidiol ("CBD") and other products containing CBD-rich hemp oil ("Legal Hemp"). Company products are formulated for the pharmaceutical, nutraceutical and cosmeceutical industries, including dietary supplements, prescription-based hemp oil for sale in countries that have legalized hemp oil for the treatment of various illnesses and conditions (such as Brazil and Mexico) and skin care products. The Company’s mission is to be the premier cannabis and hemp industry innovator, leveraging its team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit.Medical Marijuana Inc announced on June 28, 2017, that its subsidiary HempMeds® Mexico inaugurated its first office in Monterrey, Nuevo Leon, Mexico, as demand continues to grow for the Company's zero-Tetrahidrocannabidiol (THC) Real Scientific Hemp Oil-X™ (RSHO-X™) across the Country. The Company also announced that it appointed medical cannabis activist and Por Grace Foundation founder Raul Elizalde to lead the Company's strategy in Mexico as General Manager.The primary objective of the new office will be to serve as the Company's hub for the sales, marketing and distribution of RSHO-X™ to distributors and patients in Mexico. With its over 120 million residents, Mexico represents a potential $1 billion to $2 billion cannabidiol (CBD) hemp oil market over the next ten years for Medical Marijuana, Inc. RSHO-X™ was the first-ever cannabis product to receive approval from the federal government of Mexico, via a COFEPRIS permit, for importation. Medical Marijuana, Inc. CEO Dr. Stuart Titus commented:

"This new office opening is exciting, as our Company will now be operating on the ground in Mexico, a Country where medical marijuana just became officially legalized. We are confident that Raul's vast experience and diligent work for many years to make the therapeutic use of cannabinoids legal in Mexico will help our Company become even more successful in Mexico by navigating the Country's new federal laws to provide patients in the Country with access to RSHO-X™."

In other news, Medical Marijuana Inc recently made two important appointments to its management team. On July 3, 2017, the Company announced that its subsidiary Dixie Botanicals™ appointed Brent Albin as Director of Sales and Marketing. Albin brings to Dixie Botanicals® more than 10 years of experience in online advertising and social media promotion, capable of creating mass followings on social networks for organizations.On June 29, 2017, the company appointed Jim Gibson as Vice President of Operations. Gibson brings to Kannaway® more than 25 years of experience in global operations positions. His experience includes coordinating the global operations of large scale companies, and being responsible for their worldwide, end-to-end supply chain management and product delivery.Perhaps the most interesting and impactful recent news about Medical Marijuana Inc is the announcement on June 26, 2017 that the Company’s major investment company AXIM Biotechnologies Inc (OTCMKTS:AXIM), a world leader in cannabinoid research and development, filed with the United States Patent and Trademark Office (USPTO) for U.S. Application Serial Number 62/410,469, a patent of invention that involves a chewing gum composition with controlled release of cannabinoids and opioid agonists and/or antagonists for addiction and/or dependence treatment. The chewing gum may also be used for treatment of chronic pain. Medical Marijuana, Inc. CEO Dr. Stuart Titus commented:

"We are proud of AXIM Biotech on this milestone achievement that brings the Company one step closer toward entering the $100 billion market in pain management. The future of pain medicine may be a high dose of cannabis and a low dose of opioids. Already, we are seeing the incidence of prescription drug overdose death 25% lower in states where medical cannabis is legal, presumably because patients are able to combine natural botanical cannabis and use lower dose opioids to control pain."

MJNA stock has not had much movement since our last review on May 21, 2017. The latest quarterly financial reports for the period ending March 31, 2017 indicate growth in revenues, $1,535,728 to $3,612,739, and gross profit, $820,446 to $2,545,229 as compared to the same quarter of 2016. However, the Company is still operating at a Net Loss of ($2,222,818), albeit a significantly smaller loss compared to the prior year Net Loss of ($11,096,659). Total assets also show a significant increase from $214,115,665 to $494,182,096, as compared to the same quarter of 2016. Current market capitalization stands at $268.52 million, on 2.56 Billion shares outstanding as of July 3, 2017.Medical Marijuana Inc is aggressively pursuing opportunities throughout the world, giving it more opportunity for growth. It's only a matter of time before we see the stock price at much higher levels. Be sure to check out our complete coverage of MJNA for the full story. We will be updating our subscribers as soon as we know more. For the latest updates on MJNA, sign up below!Image courtesy of FlickrDisclosure: We have no position in MJNA or AXIM and have not been compensated for this article.